- Home
- GLSI vs CRDF Comparison
GLSI vs CRDF Comparison
Compare GLSI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- CRDF
- Stock Information
- Founded
- GLSI 2006
- CRDF 1999
- Country
- GLSI United States
- CRDF United States
- Employees
- GLSI N/A
- CRDF N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLSI Health Care
- CRDF Health Care
- Exchange
- GLSI Nasdaq
- CRDF Nasdaq
- Market Cap
- GLSI 149.5M
- CRDF 144.4M
- IPO Year
- GLSI 2020
- CRDF N/A
- Fundamental
- Price
- GLSI $11.28
- CRDF $2.20
- Analyst Decision
- GLSI Strong Buy
- CRDF Strong Buy
- Analyst Count
- GLSI 1
- CRDF 5
- Target Price
- GLSI $39.00
- CRDF $11.10
- AVG Volume (30 Days)
- GLSI 91.0K
- CRDF 762.3K
- Earning Date
- GLSI 11-13-2025
- CRDF 11-06-2025
- Dividend Yield
- GLSI N/A
- CRDF N/A
- EPS Growth
- GLSI N/A
- CRDF N/A
- EPS
- GLSI N/A
- CRDF N/A
- Revenue
- GLSI N/A
- CRDF $545,000.00
- Revenue This Year
- GLSI N/A
- CRDF N/A
- Revenue Next Year
- GLSI N/A
- CRDF N/A
- P/E Ratio
- GLSI N/A
- CRDF N/A
- Revenue Growth
- GLSI N/A
- CRDF N/A
- 52 Week Low
- GLSI $8.06
- CRDF $1.90
- 52 Week High
- GLSI $15.47
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- GLSI 53.71
- CRDF 52.58
- Support Level
- GLSI $9.73
- CRDF $1.99
- Resistance Level
- GLSI $10.57
- CRDF $2.13
- Average True Range (ATR)
- GLSI 0.57
- CRDF 0.10
- MACD
- GLSI 0.02
- CRDF 0.04
- Stochastic Oscillator
- GLSI 68.65
- CRDF 78.69
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.